A 58-year-old male smoker with a 30 pack-year history presents with chronic cough and hemoptysis. Bronchoscopy reveals a suspicious lesion in the left main bronchus. A biopsy shows columnar ciliated epithelium with mucin-secreting cells replacing the normal stratified squamous epithelium. Which investigation is most appropriate to assess the degree of malignant potential and guide further management?

Question

Accepted Answer

B. Histopathological grading using the WHO dysplasia classification system. ## Assessment of Dysplasia in Metaplastic Epithelium

### Clinical Context
The patient has metaplasia (replacement of stratified squamous epithelium with columnar mucin-secreting epithelium) in the bronchus—a classic response to chronic irritation from smoking. The critical next step is to determine whether dysplasia is present and grade its severity, as this directly predicts malignant transformation risk and guides surveillance vs. intervention.

### Why Histopathological Grading is the Gold Standard

**Key Point:** Histopathological grading using WHO dysplasia classification (mild, moderate, severe dysplasia, and carcinoma in situ) is the **gold standard** for assessing malignant potential in metaplastic lesions. It is:
- **Morphology-based**: evaluates nuclear size, chromatin pattern, mitotic rate, and loss of maturation
- **Prognostically validated**: directly correlates with risk of progression to invasive carcinoma
- **Clinically actionable**: guides decision-making (surveillance for mild dysplasia vs. ablation/resection for severe dysplasia/CIS)
- **Cost-effective and reproducible**: requires only standard H&E staining on the existing biopsy

**High-Yield:** The WHO dysplasia grading system is the **standard of care** for risk stratification in Barrett's esophagus, oral leukoplakia, cervical intraepithelial neoplasia, and respiratory metaplasia—all high-yield NEET PG topics.

### Dysplasia Grading Criteria

| Feature | Mild Dysplasia | Moderate Dysplasia | Severe Dysplasia / CIS |
|---------|---|---|---|
| Nuclear size | Mildly increased | Moderately increased | Markedly increased |
| Chromatin | Slightly coarse | Coarse | Coarse, irregular |
| Mitotic activity | Normal | Increased | Markedly increased, abnormal |
| Maturation | Preserved in superficial layers | Partial loss | Complete loss |
| Progression risk | ~5% per year | ~10% per year | ~30% per year |

**Clinical Pearl:** Severe dysplasia and carcinoma in situ (CIS) have indistinguishable histology—the distinction is architectural: CIS involves the full thickness of epithelium without invasion, while severe dysplasia shows some surface maturation.

### Why Dysplasia Grading Supersedes Other Tests
While p53 immunostaining, Ki-67, flow cytometry, and FISH provide molecular/functional data, they are **supplementary**, not primary decision-making tools in routine practice. Dysplasia grade remains the **most specific and clinically validated** predictor of malignant transformation.

Answer

A. Fluorescence in situ hybridization (FISH) for chromosomal aberrations

Answer

C. Immunohistochemistry for p53 and Ki-67

Answer

D. Flow cytometry for ploidy analysis

Explanation

Assessment of Dysplasia in Metaplastic Epithelium

Clinical Context

Why Histopathological Grading is the Gold Standard

Dysplasia Grading Criteria

Why Dysplasia Grading Supersedes Other Tests

Practice similar questions

Join our NEET PG community

Feature	Mild Dysplasia	Moderate Dysplasia	Severe Dysplasia / CIS
Nuclear size	Mildly increased	Moderately increased	Markedly increased
Chromatin	Slightly coarse	Coarse	Coarse, irregular
Mitotic activity	Normal	Increased	Markedly increased, abnormal
Maturation	Preserved in superficial layers	Partial loss	Complete loss
Progression risk	~5% per year	~10% per year	~30% per year